Jiangsu Yiming Biotechnology

The company's business model is centered on providing comprehensive, end-to-end services to pharmaceutical and biotechnology clients, guiding them from early-stage preclinical research and process development to GMP manufacturing and commercialization. Revenue is generated by offering a suite of services for advanced therapy medicinal products (ATMPs), including viral vectors, cell therapies (like CAR-T and CAR-NK), RNA-based products, and plasmid DNA. This one-stop-shop approach is designed to help clients navigate regulatory complexities and accelerate their product's journey to market. uBriGene has successfully supported over 20 IND filings with major regulatory bodies like the FDA and EMA.

uBriGene's service portfolio is extensive, covering process and analytical development, scale-up, and GMP-grade production of various biological components. The company specializes in plasmids, mRNA-LNP, viral vectors, and a range of cell therapy products such as CAR-T, CAR-NK, and iPSC. A key offering is its ready-to-use induced pluripotent stem cell (iPSC) banks, developed with proprietary RNA-LNP reprogramming technology, which can save clients significant time in sourcing and reprogramming donor cells. Furthermore, the company engages in strategic partnerships, such as its collaboration with Circurna, to accelerate the development of next-generation circular RNA therapeutics by providing expertise in purification and formulation. The company has expanded its global footprint through strategic acquisitions, including a multiproduct GMP manufacturing facility in Worcester, Massachusetts, from Mustang Bio, to better serve the North American market.